Journey Medical Co. (NASDAQ:DERM) Receives Average Rating of “Buy” from Analysts

Journey Medical Co. (NASDAQ:DERM) has received a consensus rating of “Buy” from the five ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.88.

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered Journey Medical from a “buy” rating to a “hold” rating in a research note on Saturday. Industrial Alliance Securities set a $10.50 target price on Journey Medical in a research note on Thursday, March 27th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research note on Thursday, May 15th.

Insiders Place Their Bets

In other Journey Medical news, CEO Claude Maraoui sold 4,834 shares of the firm’s stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $6.84, for a total transaction of $33,064.56. Following the transaction, the chief executive officer now owns 2,348,313 shares in the company, valued at $16,062,460.92. This trade represents a 0.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 15.03% of the company’s stock.

Hedge Funds Weigh In On Journey Medical

A number of hedge funds have recently added to or reduced their stakes in the stock. Titleist Asset Management LLC increased its stake in Journey Medical by 18.3% during the 1st quarter. Titleist Asset Management LLC now owns 12,900 shares of the company’s stock worth $76,000 after acquiring an additional 2,000 shares during the period. Cetera Investment Advisers increased its stake in Journey Medical by 21.8% during the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock worth $54,000 after acquiring an additional 2,478 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in Journey Medical by 3.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company’s stock worth $1,994,000 after acquiring an additional 9,938 shares during the period. Kovitz Investment Group Partners LLC increased its stake in shares of Journey Medical by 112.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after purchasing an additional 13,105 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Journey Medical in the 1st quarter valued at $110,000. Institutional investors own 7.25% of the company’s stock.

Journey Medical Price Performance

NASDAQ:DERM opened at $6.78 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The stock’s 50 day moving average price is $6.96 and its two-hundred day moving average price is $5.68. The firm has a market capitalization of $157.95 million, a price-to-earnings ratio of -7.21 and a beta of 0.87. Journey Medical has a 12-month low of $3.54 and a 12-month high of $8.25.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.14 million for the quarter, compared to analyst estimates of $12.05 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. On average, analysts anticipate that Journey Medical will post -1.02 earnings per share for the current year.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.